Shots:

• The approvals is based on P-II UNITY-NHL trial involves assessing Ukoniq (800 mg- qd) in 69 patients with MZL who has received at least 1 prior anti-CD20 based regimen and in 117 patients with FL who received at least 2 prior systemic therapies
• Results: ORR (49% vs 50%) as assessed by IRC- CR (16% vs 3.4%)- PR (33% vs 39%)- DoR of FL was 11.1 mos.
• Ukoniq is the 1^st oral inhibitor of PI3K delta and CK1 epsilon. Additionally- it has received BTD for MZL and ODD for MZL and FL

 ­ Ref: TG Therapeutics | Image: Seeking Alpha